9-Me-BC
Dopaminergic, Neuroprotection
No human pharmacokinetic data exists — no Phase 1 or later trial has been published. The structural analogue harman shows roughly 68 minutes in human plasma, but that is a different molecule and is not a substitute.
In short
- No human study of any kind has been published — no Phase 1, no pharmacokinetics, no safety data.
- Rodent work reports stimulation and protection of dopaminergic neurons, dendritic growth, and anti-inflammatory effects.
- It is a monoamine oxidase inhibitor, which is the single most important practical fact about it because MAO inhibition carries real interaction risk.
- Beta-carbolines as a chemical class include compounds with documented genotoxicity concerns; 9-Me-BC itself has not been cleared of these.
- Research compound only. Not approved anywhere.
Structure
How it works
9-methyl-beta-carboline is a small alkaloid reported in rodent studies to increase dopamine levels in the hippocampus and substantia nigra, promote dendritic and synaptic proliferation, and exert anti-inflammatory effects on glial cells.
It inhibits monoamine oxidase, with reported IC50 values around 1 µM for MAO-A and 15.5 µM for MAO-B — substantially more selective for MAO-A. MAO-A inhibition is the mechanism behind the dietary and drug interactions associated with that drug class.
Metabolism is described as hydroxylation at position 6 followed by conjugation. None of this has been confirmed in humans.
What the research shows
In rodents, reported effects include improved performance on spatial learning tasks, increased hippocampal dopamine, and protection of dopaminergic neurons in models of neurodegeneration.
There are no human results, because there have been no human studies. Reports of cognitive or mood effects in people are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Rat — cognitive and dopaminergic studies | Low milligram-per-kilogram ranges, varying by model | intraperitoneal or oral | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, usually in short courses | 5–20 mg daily | oral |
There is no human dose, no human half-life, and no toxicology. The half-life sometimes quoted online (~68 minutes) belongs to harman, a structurally related but different molecule, and is not applicable. Because the compound inhibits MAO-A, the interaction profile is a more pressing concern than the dose.
Handling and storage
Oral, as powder or capsules from research-chemical vendors. Short courses with breaks are the commonly described pattern, generally reasoned from the MAO inhibition rather than from any study.
No route, timing, or duration has been established in humans.
Side effects
No human safety data exists. No toxicology study has been published.
The concrete concern is MAO-A inhibition. Clinically used MAO-A inhibitors carry dietary restrictions on tyramine-containing foods (aged cheese, cured meats, some fermented products) because the combination can produce hypertensive crisis, and they interact seriously with serotonergic drugs including SSRIs, SNRIs, triptans, and tramadol, where the risk is serotonin syndrome. Whether 9-Me-BC inhibits MAO-A sufficiently in humans to reproduce these risks is unknown — which is not the same as knowing it does not.
Separately, some beta-carboline alkaloids have raised genotoxicity and co-mutagenicity concerns. 9-Me-BC specifically has not been shown to carry them, and has also not been shown not to.
Combinations
The MAO-A activity makes this the compound in this library where combination is most likely to cause acute harm. Combining with any serotonergic agent — antidepressants, triptans, tramadol, dextromethorphan — is the specific pattern that produces serotonin syndrome with established MAO inhibitors.
No interaction study exists for this compound. The absence of data is not reassurance.
Research status
The literature consists of rodent studies, largely from a small number of German groups, covering dopaminergic stimulation, neuroprotection, and anti-inflammatory effects.
No Phase 1 or later human trial has been registered or published.
Legal status
Not approved for human use in any jurisdiction. Not scheduled as a controlled substance in most countries, which reflects the absence of any assessment rather than a safety finding. Sold labelled for research use only.
WADA status
Not specifically listed. Falls under WADA class S0 as a substance not approved by any governmental regulatory health authority for human therapeutic use, and should be treated as prohibited in sport.
Conclusion
9-Me-BC has an interesting preclinical dopaminergic profile and zero human characterisation. Of everything in this library it is the compound where the gap between online enthusiasm and available evidence is widest.
The MAO-A inhibition is the part that deserves attention before dosing, not after. If you take anything serotonergic — including common antidepressants — that interaction is the concrete, documented-in-the-drug-class risk here.
Sources
Track your own 9-Me-BC protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.